[Predictors of prolonged intensive care unit stay in patients undergoing aortic arch replacement].

Qian Lei(University of Electronic Science and Technology of China), Lihuan Li(Peking Union Medical College Hospital), Lei Chen(Zhuzhou Central Hospital), Lizhong Sun(Yale New Haven Hospital), Qian Chang, Nengxin Fang(Chinese Academy of Medical Sciences & Peking Union Medical College)
PubMed
June 1, 2009
Cited by 0

Related Papers

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k
Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma
|New England Journal of Medicine|2019|934
Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial
|The Lancet|2021|234
High serum cortisol level is associated with increased risk of delirium after coronary artery bypass graft surgery: a prospective cohort study
|Critical Care|2010|187